ZA953440B - Bifunctional protein ppeparation and use - Google Patents

Bifunctional protein ppeparation and use

Info

Publication number
ZA953440B
ZA953440B ZA953440A ZA953440A ZA953440B ZA 953440 B ZA953440 B ZA 953440B ZA 953440 A ZA953440 A ZA 953440A ZA 953440 A ZA953440 A ZA 953440A ZA 953440 B ZA953440 B ZA 953440B
Authority
ZA
South Africa
Prior art keywords
sub
hinge region
zeta
bifunctional protein
joined
Prior art date
Application number
ZA953440A
Other languages
English (en)
Inventor
Bernd Groner
Dirk Moritz
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of ZA953440B publication Critical patent/ZA953440B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA953440A 1994-05-02 1995-04-28 Bifunctional protein ppeparation and use ZA953440B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94810244 1994-05-02

Publications (1)

Publication Number Publication Date
ZA953440B true ZA953440B (en) 1995-11-02

Family

ID=8218248

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA953440A ZA953440B (en) 1994-05-02 1995-04-28 Bifunctional protein ppeparation and use

Country Status (18)

Country Link
US (1) US6984382B1 (no)
EP (1) EP0758394B1 (no)
JP (1) JP3742103B2 (no)
KR (1) KR100373813B1 (no)
AT (1) ATE228166T1 (no)
AU (1) AU694222B2 (no)
CA (1) CA2188422C (no)
DE (1) DE69528894T2 (no)
DK (1) DK0758394T3 (no)
ES (1) ES2185705T3 (no)
FI (1) FI119191B (no)
IL (1) IL113530A0 (no)
NO (1) NO316923B1 (no)
NZ (1) NZ285395A (no)
PT (1) PT758394E (no)
TW (1) TW428026B (no)
WO (1) WO1995030014A1 (no)
ZA (1) ZA953440B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995030014A1 (en) 1994-05-02 1995-11-09 Ciba-Geigy Ag Bifunctional protein, preparation and use
EP0870040A2 (en) * 1995-12-29 1998-10-14 Chiron Corporation Gene delivery vehicle-targeting ligands
AU4373197A (en) * 1996-09-19 1998-04-14 Diagnocure Inc. Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
DE10121113A1 (de) * 2001-04-28 2002-10-31 Gabriele Pecher Genmodifizierte YT Zelllinie und ihre Verwendung
DK2112162T3 (da) 2004-07-10 2015-02-23 Fox Chase Cancer Ct Genetisk modificerede humane naturlige dræbercellelinjer
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
EP2298815B1 (en) 2005-07-25 2015-03-11 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
KR101571027B1 (ko) * 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
WO2008045437A2 (en) * 2006-10-09 2008-04-17 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
PT3012268T (pt) 2010-09-08 2018-01-31 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Recetores de antigénio quimérico com uma região de charneira otimizada
KR102243575B1 (ko) 2010-12-09 2021-04-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
ES2719495T3 (es) 2012-05-07 2019-07-10 Dartmouth College Anticuerpo dirigido contra b7-h6, proteínas de fusión, y métodos de uso de los mismos
KR102313997B1 (ko) 2013-02-20 2021-10-20 노파르티스 아게 인간화 항-EGFRvIII 키메라 항원 수용체를 사용한 암의 치료
EP3744736A1 (en) 2013-02-20 2020-12-02 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
WO2014145252A2 (en) 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
AU2014366047B2 (en) 2013-12-19 2021-03-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
ES2963718T3 (es) 2014-01-21 2024-04-01 Novartis Ag Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
HRP20240874T1 (hr) 2014-04-07 2024-10-11 Novartis Ag Liječenje raka korištenjem kimernog antigenskog receptora anti-cd19
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
CA2955154C (en) 2014-07-21 2023-10-31 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
AU2015292811B2 (en) 2014-07-21 2019-12-19 Novartis Ag Treatment of cancer using a CLL-1 chimeric antigen receptor
MX2017001011A (es) 2014-07-21 2018-05-28 Novartis Ag Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
ES2791248T3 (es) 2014-08-19 2020-11-03 Novartis Ag Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
AU2015317608B2 (en) 2014-09-17 2021-03-11 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
RU2743657C2 (ru) 2014-10-08 2021-02-20 Новартис Аг Биомаркеры, прогнозирующие способность к терапевтическому ответу на терапию химерным рецептором антигена, и их применение
WO2016109410A2 (en) 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
RU2752918C2 (ru) 2015-04-08 2021-08-11 Новартис Аг Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) k cd19
EP3283619B1 (en) 2015-04-17 2023-04-05 Novartis AG Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
CN109476722A (zh) 2015-07-21 2019-03-15 诺华股份有限公司 用于改善免疫细胞的功效和扩张的方法
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
JP6905163B2 (ja) 2015-09-03 2021-07-21 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア サイトカイン放出症候群を予測するバイオマーカー
SG10202002577XA (en) 2015-09-21 2020-04-29 Aptevo Res & Development Llc Cd3 binding polypeptides
IL295858A (en) 2015-12-04 2022-10-01 Novartis Ag Preparations and methods for immuno-oncology
JP7082055B2 (ja) 2015-12-22 2022-06-07 ノバルティス アーゲー 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体（ｃａｒ）およびｐｄ－ｌ１阻害剤に対する抗体
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
TW202340473A (zh) 2016-10-07 2023-10-16 瑞士商諾華公司 利用嵌合抗原受體之癌症治療
ES2912408T3 (es) 2017-01-26 2022-05-25 Novartis Ag Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
EP3601561A2 (en) 2017-03-22 2020-02-05 Novartis AG Compositions and methods for immunooncology
EP3697436A1 (en) 2017-10-18 2020-08-26 Novartis AG Compositions and methods for selective protein degradation
CA3089319A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
SG11202011830SA (en) 2018-06-13 2020-12-30 Novartis Ag Bcma chimeric antigen receptors and uses thereof
CN110627895B (zh) * 2018-06-25 2021-03-23 北京大学 肺癌特异性tcr及其分析技术和应用
CA3110905A1 (en) 2018-08-31 2020-03-05 Invectys SA Chimeric antigen receptors against multiple hla-g isoforms
EP3956666A1 (en) * 2019-04-18 2022-02-23 GlaxoSmithKline Biologicals S.A. Antigen binding proteins and assays
US11975026B2 (en) 2019-11-26 2024-05-07 Novartis Ag CD19 and CD22 chimeric antigen receptors and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE260880T1 (de) 1986-09-11 1988-11-03 Dana-Farber Cancer Institute, Inc., Boston, Mass. Verfahren zur ausloesung der zytotoxizitaet.
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
FI105320B (fi) 1988-04-04 2000-07-31 Oncogen Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa
AU656544B2 (en) 1990-10-31 1995-02-09 Brigham And Women's Hospital Genetic modification of endothelial cells
ES2096749T3 (es) * 1990-12-14 1997-03-16 Cell Genesys Inc Cadenas quimericas para vias de transduccion de señal asociada a un receptor.
AU662311B2 (en) * 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
FR2672901B1 (fr) 1991-02-15 1994-09-30 Immunotech Sa Nouvelles molecules de dna recombinants codant pour une chaine du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant.
WO1992015326A1 (en) 1991-02-27 1992-09-17 The Regents Of The University Of California Targeting complex mediated immunogenicity
IL101147A (en) 1991-03-07 2004-06-20 Gen Hospital Corp Change of direction of cellular immunity by chimera receptors
US5939531A (en) 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
WO1993019163A1 (en) * 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
EP0565794A1 (en) 1992-04-14 1993-10-20 British Biotech Pharmaceuticals Limited Induction of CTL responses
WO1995030014A1 (en) 1994-05-02 1995-11-09 Ciba-Geigy Ag Bifunctional protein, preparation and use

Also Published As

Publication number Publication date
FI964311A (fi) 1996-10-25
DE69528894D1 (de) 2003-01-02
NO964641L (no) 1996-11-01
EP0758394A1 (en) 1997-02-19
KR100373813B1 (ko) 2003-10-08
DE69528894T2 (de) 2003-03-27
DK0758394T3 (da) 2003-03-03
FI964311A0 (fi) 1996-10-25
WO1995030014A1 (en) 1995-11-09
ATE228166T1 (de) 2002-12-15
JPH09512176A (ja) 1997-12-09
JP3742103B2 (ja) 2006-02-01
NZ285395A (en) 1998-10-28
AU2446995A (en) 1995-11-29
IL113530A0 (en) 1995-07-31
CA2188422A1 (en) 1995-11-09
CA2188422C (en) 2011-03-15
US6984382B1 (en) 2006-01-10
PT758394E (pt) 2003-04-30
ES2185705T3 (es) 2003-05-01
FI119191B (fi) 2008-08-29
EP0758394B1 (en) 2002-11-20
NO316923B1 (no) 2004-06-28
NO964641D0 (no) 1996-11-01
AU694222B2 (en) 1998-07-16
TW428026B (en) 2001-04-01

Similar Documents

Publication Publication Date Title
ZA953440B (en) Bifunctional protein ppeparation and use
IL112390A0 (en) A cell which expresses chimeric receptors, DNA and vectors encoding said receptors and pharmaceutical compositions containing the same
WO2000023573A3 (en) Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
NZ333915A (en) Soluble monovalent and multivalent MHC class II fusion proteins
KR100271382B1 (en) Human receptor h4-1bb
AU6059096A (en) CTLA4 mutant molecules and uses thereof
WO2002077029A3 (en) Cd19-specific redirected immune cells
NZ332598A (en) Human BAS-1 protein, and use as an antagonist for modulating physiology or development of a cell
NZ527297A (en) Immunosuppression by blocking T cell co-stimulation signal 2 (B7/CD28 interaction)
WO1999000010A3 (en) TRANSGENIC ANIMALS EXPRESSING HUMAN Fc RECEPTORS
HK1001464A1 (en) Receptor on the surface of activated t-cells:acts-4
NO934801L (no) CTL4A reseptor, fusjonsproteiner som inneholder den og anvendelse derav
CA2312667A1 (en) Novel cytokine
KR927003847A (ko) 수용체-결합된 신호 변환 경로를 위한 키메라 사슬
ES2093623T3 (es) Receptores monovalentes y oligovalentes, bioespecificos y oligoespecificos, su preparacion y empleo.
AU1914795A (en) Monoclonal antibodies specific to vegf receptors and uses thereof
GR3030415T3 (en) Platelet activating factor antagonists.
AU1868695A (en) Immuno-stimulatory monoclonal antibodies
WO1996021028A3 (en) Soluble heterodimeric t cell receptors and their antibodies
AU2525597A (en) Monoclonal antibodies binding human growth hormone (hgh)
AU2002323894A1 (en) Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use
WO2001042297A3 (en) Clasp-3 transmembrane protein
WO2001042294A3 (en) Clasp-4 transmembrane protein
MX9801253A (es) Proteinas de fusion de alergeno -xc032.
HUP0001579A2 (en) Cell surface molecule mediating cell adhesion and signal transmission